23andMe (ME) Competitors

23andMe (NASDAQ:ME) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.

Does the MarketBeat Community favor ME or CLSD?

Clearside Biomedical received 361 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 67.45% of users gave Clearside Biomedical an outperform vote while only 46.15% of users gave 23andMe an outperform vote.

Company	Underperform	Outperform
23andMe	Outperform Votes 12 46.15%	Underperform Votes 14 53.85%
Clearside Biomedical	Outperform Votes 373 67.45%	Underperform Votes 180 32.55%

Which has more volatility and risk, ME or CLSD?

23andMe has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Which has better earnings and valuation, ME or CLSD?

Clearside Biomedical has lower revenue, but higher earnings than 23andMe. Clearside Biomedical is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
23andMe	$208.78M	0.06	-$666.70M	-$15.45	-0.03
Clearside Biomedical	$7.70M	9.24	-$32.49M	-$0.47	-2.00

Do institutionals and insiders believe in ME or CLSD?

36.1% of 23andMe shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 26.3% of 23andMe shares are held by company insiders. Comparatively, 9.2% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer ME or CLSD?

In the previous week, 23andMe had 40 more articles in the media than Clearside Biomedical. MarketBeat recorded 55 mentions for 23andMe and 15 mentions for Clearside Biomedical. Clearside Biomedical's average media sentiment score of 0.30 beat 23andMe's score of -0.17 indicating that Clearside Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
23andMe	4 Very Positive mention(s)	5 Positive mention(s)	29 Neutral mention(s)	10 Negative mention(s)	5 Very Negative mention(s)	Neutral
Clearside Biomedical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ME or CLSD more profitable?

23andMe has a net margin of -183.39% compared to Clearside Biomedical's net margin of -413.83%. Clearside Biomedical's return on equity of 0.00% beat 23andMe's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
23andMe	-183.39%	-170.07%	-62.13%
Clearside Biomedical	-413.83%	N/A	-92.90%

Do analysts prefer ME or CLSD?

23andMe currently has a consensus target price of $9.40, indicating a potential upside of 1,787.55%. Clearside Biomedical has a consensus target price of $5.25, indicating a potential upside of 459.70%. Given 23andMe's higher probable upside, analysts clearly believe 23andMe is more favorable than Clearside Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
23andMe	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Clearside Biomedical	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Clearside Biomedical beats 23andMe on 10 of the 18 factors compared between the two stocks.